title: The evolving potential of companion diagnostics.
abstract: The scope of companion diagnostics in cancer has undergone significant shifts in the past few years, with increased development of targeted therapies and novel testing platforms. This has provided new opportunities to effect unprecedented paradigm shifts in the application of personalized medicine principles for patients with cancer. These shifts involve assay platforms, analytes, regulations, and therapeutic approaches. As opportunities involving each of these facets of companion diagnostics expand, close collaborations between key stakeholders should be enhanced to ensure optimal performance characteristics and patient outcomes.
authors.affiliation: a Division of Pathology and Laboratory Medicine, Department of Hematopathology , the University of Texas M.D. Anderson Cancer Center , Houston , TX , USA.
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Khoury
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001681:Biological Assay / Q000592:standards; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D002986:Clinical Trials as Topic; D004273:DNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000295:instrumentation / Q000379:methods*; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D057285:Precision Medicine / Q000295:instrumentation / Q000379:methods*; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D012107:Research Design
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D012334:RNA, Neoplasm
keywords: Cancer; companion diagnostics; molecular diagnostics; next-generation sequencing